Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 4/20 | 0.60 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.60 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17177676 | 0.92 | KLK7 (0.51) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL2584726 | 0.92 | KLK7 (0.51) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL3873338 | 0.92 | KLK7 (0.55) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL8059266 | 0.92 | KLK7 (0.55) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL13702221 | 0.90 | KLK7 (0.49) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL29401078 | 0.90 | KLK7 (0.49) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL29808549 | 0.90 | KLK7 (0.49) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL29401961 | 0.89 | CASP1 (0.51) | KLK7KLK5CTSLCASP1CTSK | |
| SCHEMBL2449438 | 0.87 | PPARA (0.62) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL357466 | 0.87 | PPARA (0.62) | KLK7KLK5PPARACTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | MOLECURE S.A. (PL) | 2026-04-28 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4267590-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ONCOARENDI THERAPEUTICS S.A. (PL) | 2023-11-01 | — | — | EP | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-06-13 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022137156-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | Oncoarendi Therapeutics S.A. (PL) | 2022-06-30 | — | — | WO | disclosed |
| US-20220204530-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | MOLECURE S.A. (PL) | 2022-06-30 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204530-A1 | ARGINASE INHIBITORS AND METHODS OF USE THEREOF | ARG1, ARG2, PRMT1 | KLK7 1747/4885KLK5 1342/4885CACNA1B 4667/4885 |
| US-11673912-B2 | Continuous, solvent-free and non-enzymatic peptide synthesis by reactive extrusion | QPCT, ANPEP, PEPD | KLK7 3066/4885KLK5 2786/4885CACNA1B 4841/4885 |
| US-12612420-B2 | Arginase inhibitors and methods of use thereof | ARG1, ARG2, ARGLU1 | KLK7 4717/4885KLK5 4299/4885CACNA1B 3288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.